JPRN-UMIN000044136已完成未知
Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G) - Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of chemotherapy including regorafenib, FTD/TPI, or investigational drug prior to FTD/TPI plus BEV
研究者
相似试验
已完成
2 期
A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapyER-positive breast cancerHer2 negative10006291Metastatic breast cancerNL-OMON52884BOOG Study Center50
进行中（未招募）
2 期
TAS102 in patients with ER-positive, HER2-negative advanced breast cancer (TIBET study)Advanced breast cancer2024-519204-27-00BOOG Study Center B.V.50
尚未招募
Unknown
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancerJPRN-UMIN000051378The 22nd Century Cutting-Edge Medical Informaion Technology Organization15
进行中（未招募）
1 期
Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancerPatients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.EUCTR2018-002936-26-DEHeinrich-Heine-University Düsseldorf28
进行中（未招募）
1 期
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroesophageal cancerCTIS2023-508724-35-00nicancer73